Takeda to acquire exclusive worldwide (ex-China) license of HUTCHMED’s Fruquintinib Ruchika Sharma26 Jan 2023 10:00 AM GMTUnder the terms of the agreement, Takeda will receive an exclusive worldwide license to develop and commercialize fruquintinib in all indications and...
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib Isra Zaman13 Sep 2022 4:00 AM GMTResearchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly...
